SANTONI, MASSIMO
 Distribuzione geografica
Continente #
NA - Nord America 295
EU - Europa 175
AS - Asia 78
OC - Oceania 3
AF - Africa 1
SA - Sud America 1
Totale 553
Nazione #
US - Stati Uniti d'America 286
IE - Irlanda 135
CN - Cina 73
FI - Finlandia 23
CA - Canada 9
DE - Germania 7
IT - Italia 6
JP - Giappone 5
SE - Svezia 3
AU - Australia 2
AR - Argentina 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
Totale 553
Città #
Dublin 135
Chandler 87
Beijing 52
Ashburn 34
Helsinki 23
Lawrence 20
Medford 20
Princeton 20
Shanghai 19
Wilmington 11
Toronto 8
Dearborn 5
Tokyo 5
Norwalk 3
Boardman 2
Canberra 2
Milan 2
Cambridge 1
Cedar Knolls 1
Changsha 1
Fairfield 1
Gunzenhausen 1
Nanchang 1
Ottawa 1
Pavia 1
Pinehaven 1
Piscataway 1
Pognana Lario 1
Saint Petersburg 1
San Francisco 1
Torino 1
Totale 462
Nome #
Clinical impact of Pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis 37
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 37
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 34
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 33
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 33
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 32
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 32
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 31
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 30
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises 29
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 28
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis 28
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 27
Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma 27
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 26
Transplantation of kidneys with tumors 24
Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis 24
Toward a genome-based treatment landscape for renal cell carcinoma 22
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End 21
Renal cancer in kidney transplanted patients 20
Totale 575
Categoria #
all - tutte 3.552
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.552


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202079 0 0 0 0 0 0 21 6 0 24 28 0
2020/20214 0 1 0 0 0 0 0 3 0 0 0 0
2021/202285 3 0 9 0 1 0 1 5 2 3 15 46
2022/2023296 34 32 5 8 14 25 0 15 152 3 6 2
2023/2024111 21 18 3 5 10 25 12 4 0 1 3 9
Totale 575